Inhaled mannitol for cystic fibrosis.

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Genetics

Background:

• Cystic fibrosis (CF) management involves airway secretion clearance.
• Mannitol is an agent that may enhance mucociliary clearance.
• Dry powder mannitol offers a potentially more convenient alternative to nebulized treatments.

Purpose of the Study:

• Assess mannitol's tolerability, impact on quality of life, and respiratory function in CF patients.
• Identify adverse events associated with inhaled dry powder mannitol therapy.

Main Methods:

• Systematic review of randomized controlled trials comparing mannitol to placebo, active comparators, or no treatment.
• Data extraction and risk of bias assessment by independent authors.
• Quality of evidence assessed using GRADE methodology.

Main Results:

• Moderate-quality evidence shows mannitol improves lung function (FEV1) over six months compared to control.
• Low to very low-quality evidence indicates no consistent difference in quality of life.
• Adverse events like cough and bronchospasm were reported but not significantly different between groups.

Conclusions:

• Mannitol may be considered for CF treatment, with moderate evidence for lung function improvement.
• Low-quality evidence suggests no significant difference when compared to dornase alfa.
• Further research is needed to determine optimal patient selection, long-term efficacy, and comparative effectiveness against other mucolytics.